Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2008-01-24
2011-11-08
Lundgren, Jeffrey S (Department: 1629)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
Reexamination Certificate
active
08053444
ABSTRACT:
The present invention relates to a stable pharmaceutical composition that includes sirolimus. The pharmaceutical composition includes sirolimus in the amorphous form, a fatty acid ester, such as glyceryl behenate, and a pharmaceutically acceptable polymer wherein the fatty acid ester is present at a concentration of less than 10% w/w compared to the total weight of the composition.
REFERENCES:
patent: 3929992 (1975-12-01), Sehgal et al.
patent: 2003/0180352 (2003-09-01), Patel et al.
patent: 2003/0211160 (2003-11-01), Guitard et al.
patent: 0868911 (1998-10-01), None
patent: 1092429 (2001-04-01), None
patent: WO2006/039237 (2006-04-01), None
patent: WO2006/094507 (2006-09-01), None
Morissette et al. (Advanced Drug Delivery Reviews, vol. 56, pp. 275-300; 2004).
Vippagunta et al. (Advanced Drug Delivery Reviews, vol. 48, Abstract; 2001).
Jerala-Strukelj Zdenka
Legen Igor
Reven Sebastjan
Blakely, III Nelson
Lek Pharmaceuticals d.d.
Luedeka Neely & Graham P.C.
Lundgren Jeffrey S
LandOfFree
Sirolimus formulation does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Sirolimus formulation, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Sirolimus formulation will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4296225